Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone + Azacitidine + Venetoclax in Newly Diagnosed Elderly or Unfit AML
NCT07828535Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity up to 42 days, Incidence of treatment-related adverse events and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07828535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828535.